Boehringer In­gel­heim scraps $600M+ lung can­cer pro­gram with Cure­Vac, as the biotech preps its sec­ond Covid-19 shot

The Ger­man biotech Cure­Vac re­leased its sec­ond quar­ter up­date Mon­day morn­ing, and dis­closed among the Covid-19 vac­cine high­lights that a $600 mil­lion-plus on­col­o­gy part­ner­ship with Boehringer In­gel­heim has been ter­mi­nat­ed.

Cure­Vac and Boehringer had been work­ing to de­vel­op the mR­NA can­cer vac­cine can­di­date since 2014, when Cure­Vac re­ceived about $45 mil­lion up­front and near­ly $556 mil­lion in promised mile­stones. Boehringer de­cid­ed to pull the plug in June, and the ter­mi­na­tion will be­come ef­fec­tive this No­vem­ber, the com­pa­nies said, and a Phase I/II com­bo ther­a­py study re­mains on­go­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER